/INTS
INTS Stock - Intensity Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.41-1.75%
$0.01 (-1.75%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.14
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1118.3%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INTS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.41 – $0.41
TARGET (TP)$5.00
STOP LOSS$0.38
RISK/REWARD1:151.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.24
52W High$3.17
52W Low$0.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-147,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-16,585,000 | $-8,319,000 | $-7,550,000 | $-8,013,722 | $-6,223,246 |
| Net Income | $-16,268,000 | $-10,538,000 | $-7,582,000 | $-7,895,600 | $-5,956,471 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.17 | $-0.87 | $-0.58 | $-0.60 | $-0.46 |
Company Overview
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
INTSBeat Rate
33%
Last 9 quarters
Avg Surprise
-48.4%
EPS vs Estimate
Beats / Misses
3/5
1 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
+33.3%
$-0.12vs$-0.18
Q2 24
No data
Q3 24
-12.5%
$-0.36vs$-0.32
Q4 24
+7.4%
$-0.25vs$-0.27
Q1 25
+4.3%
$-0.22vs$-0.23
Q2 25
-4.8%
$-0.22vs$-0.21
Q3 25
-116.7%
$-0.13vs$-0.06
Q4 25
0.0%
$-0.06vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2025 | Aug 7, 2025 | $-0.06 | $-0.13 | -116.7% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.32 | $-0.36 | -12.5% | ✗ MISS |
Q2 2024 | May 9, 2024 | — | $-0.34 | — | — |
Q1 2024 | Mar 14, 2024 | $-0.18 | $-0.12 | +33.3% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.09 | $-0.17 | -88.9% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.40 | $-1.43 | -257.5% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | — | $-0.10 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.12 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.50 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.11 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.18 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.13 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.12 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.11 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.06 | — | — |
Latest News
Intensity Therapeutics Has Been Granted U.S. Patent Number 12,496,345 Titled "Method of treating cancer"
📈 PositiveBenzinga•Dec 16, 2025, 09:04 PM
Intensity Therapeutics To Present SABCS Posters Highlighting INVINCIBLE‑4 TNBC Safety Data With 50% Fewer Grade ≥3 AEs And Phase 3 Design Overview For INT230‑6
📈 PositiveBenzinga•Dec 11, 2025, 12:59 PM
Intensity Therapeutics Granted 180-Day Extension To Regain Nasdaq Compliance
➖ NeutralBenzinga•Dec 5, 2025, 12:31 PM
Intensity Therapeutics shares are trading higher after the company announced two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium.
📈 PositiveBenzinga•Dec 4, 2025, 02:03 PM
Intensity Therapeutics Announces Two Presentations At 2025 SABCS, Highlighting Anthracycline-Free Breast Cancer Therapy Combinations and Early TNBC Trial Results
📈 PositiveBenzinga•Dec 4, 2025, 12:58 PM
Intensity Therapeutics Q3 EPS $(0.06) Beats $(0.10) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:44 PM
Intensity Therapeutics shares are trading lower after the company announced the pricing of its $4 million offering of 5 million shares at a purchase price of $0.80 per share.
📉 NegativeBenzinga•Oct 31, 2025, 02:32 PM
Intensity Therapeutics Prices 5M Share Registered Direct Offering At $0.80/Share
➖ NeutralBenzinga•Oct 31, 2025, 12:02 PM
Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset
📈 PositiveSeeking Alpha•Oct 30, 2025, 10:04 PM
Intensity Therapeutics shares are trading higher after the company announced the publication of its INT230-6 clinical results in eBioMedicine.
📈 PositiveBenzinga•Oct 30, 2025, 01:07 PM
Intensity Therapeutics Announces Publication Of INT230-6 Clinical Results In eBioMedicine
➖ NeutralBenzinga•Oct 30, 2025, 11:32 AM
Intensity Therapeutics shares are trading lower after the company reported an update on the INVINCIBLE-4 trial.
📉 NegativeBenzinga•Sep 10, 2025, 05:36 PM
Intensity Therapeutics Reports Early Radiological And Pathological Results With INT230 6 Demonstrating High Drug Absorption Tumor Necrosis And Evidence Of Immune Activation
📈 PositiveBenzinga•Sep 10, 2025, 11:49 AM
Benchmark Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $1.5
➖ NeutralBenzinga•Aug 20, 2025, 12:59 PM•Also:
Intensity Therapeutics GAAP EPS of -$0.13
📉 NegativeSeeking Alpha•Aug 7, 2025, 10:11 PM
Intensity Therapeutics raises $6.6M via at-the-market offering
➖ NeutralSeeking Alpha•Aug 4, 2025, 01:55 PM
Intensify Therapeutics slumps 27%, prices $2M stock offering
📉 NegativeSeeking Alpha•Jun 12, 2025, 06:52 AM
Intensity Therapeutics shares plummet on proposed public offering
📉 NegativeSeeking Alpha•Jun 11, 2025, 08:21 PM
Intensity Therapeutics plunges on $2.35M public offering
📉 NegativeSeeking Alpha•Apr 25, 2025, 01:14 PM
Frequently Asked Questions about INTS
What is INTS's current stock price?
Intensity Therapeutics, Inc. (INTS) is currently trading at $0.41 per share. The stock has moved -1.75% today.
What is the analyst price target for INTS?
The average analyst price target for INTS is $5.00, based on 1 analyst.
What sector is Intensity Therapeutics, Inc. in?
Intensity Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INTS's market cap?
Intensity Therapeutics, Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does INTS pay dividends?
No, Intensity Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
Explore stocks similar to INTS for comparison